The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | HIPEC and IORT do not improve survival outcomes in gastric cancer
Shouki Bazarbashi, MBBS, Alfaisal University & King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, comments on the impact of prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) and intraoperative radiotherapy (IORT) on recurrence and survival in localized gastric cancer patients undergoing gastrectomy. A retrospective study compared patients who underwent curative resection with those receiving additional HIPEC/IORT. Results showed no significant improvement in relapse-free survival (RFS) or overall survival (OS) for the HIPEC/IORT group compared to standard surgery. Hospital stays were longer in the HIPEC/IORT group. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
